알레르기 진단 시장 : 제품 및 서비스별, 검사 유형별, 알레르겐별, 최종 사용자별, 지역별 예측(-2031년)

The allergy diagnostic market is projected to reach USD 10.77 billion by 2030 from USD 6.80 billion in 2025, at a CAGR of 9.6% during the forecast period.

Technological innovation in allergy diagnostics is a key driver of growth, making testing more accurate, faster, and comprehensive. Traditional diagnostic methods such as skin prick tests (SPT) and single, allergen blood IgE tests are still of use, but the advanced platforms like multiplex immunoassays, component resolved diagnostics (CRD), and molecular allergology have surpassed them in a variety of ways. Multiplex platforms allow simultaneous detection of IgE responses to dozens or even hundreds of allergens in a single sample, thereby decreasing the time, cost, and effort for the patient. CRD is a step further in that it pinpoints the exact protein molecules within the allergens that are the cause of sensitization, thus increasing how clinically relevant the test is and risk stratification; e.g. , it can differentiate between innocent pollen sensitization and cross-reactivity that is a predictor of severe reactions.

Molecular diagnostics are also instrumental in personalized medicine-they generate the individual sensitization profile map, which doctors use for the personalization of immunotherapy treatments. Automation and digital integration with electronic health records facilitate the working processes in clinical laboratories and are also of assistance when it comes to undertaking large-scale screening programs. Point-of-care (POC) innovations that deliver quick results right in doctors' or pharmacies' offices enhance patients' convenience and the effectiveness of medical care. Apart from that, AI-powered interpretation tools are being developed to help doctors make sense of complicated allergen profiles. Such technological innovations not only improve test performance and patient experience but also represent a long-term market expansion in which diagnostic precision becomes the standard of care.

Based on product & service: The global increase in allergic diseases is a significant factor that explains why consumables have the leading share in the allergy diagnostic market. A combination of factors such as the explosive growth of cities, the deterioration of the environment, alterations in lifestyles, changes in diet, and global warming has, among other things, led to a rise in food allergies, allergic rhinitis, asthma, and atopic dermatitis. Correspondingly, the growing patient population results in higher diagnostic testing volumes, particularly laboratory-based in vitro tests, which are highly dependent on consumables. Numerous reagents and allergen-specific kits are required for each diagnostic episode; thus, the demand for consumables is further increased. Besides that, both children and elderly pediatric and geriatric populations are among the most susceptible to allergies and, therefore, often necessitate repeated and confirmatory tests. Consumables remain the most directly affected and fastest-growing source of revenue as the disease burden escalates worldwide, especially in the Asia Pacific and emerging markets.

Based on test type: A powerful incentive for the widespread adoption of in vivo testing, among other things, is the possibility of delivering test results within 15-30 minutes during a single patient visit. Such instant feedback enables doctors to identify allergies, advise patients, and start therapy plans right away. In vivo tests offer a workflow that is much more efficient, with rapid diagnosis compared to in vitro tests, which are subjected to laboratory processing and require a longer turnaround time. Besides patient satisfaction, fast diagnosis is important because it reduces patient revisits, both of which factors make the tests more appealing to outpatient clinics and hospital settings, thereby leading to higher utilization and market share for these tests.

North America holds the largest market share in the allergy diagnostic market. The North American region has a sophisticated healthcare ecosystem that strongly promotes the use of allergy diagnostics at scale. The area is well-equipped with a variety of hospitals, specialty allergy clinics, diagnostic laboratories, and reference labs equipped with advanced testing equipment. The presence of automated immunoassay analyzers, multiplex testing systems, and centralized lab services ensures high test accuracy and speed. In addition, the diagnostics are so well integrated into clinical workflows that doctors can easily order allergy tests as standard of care, thereby supporting the market leader's dominance.

A breakdown of the primary participants (supply-side) for the allergy diagnostic market referred to in this report is provided below:

• By Company Type: Tier 1: 34%, Tier 2: 38%, and Tier 3: 28%
• By Designation: C-level: 26%, Director Level: 35%, and Others: 39%
• By Region: North America: 35%, Europe: 30%, Asia Pacific: 25%, Latin America: 6%, Middle East & Africa: 2%, GCC Countries: 3%

Prominent players in the allergy diagnostic market are Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Minaris Medical America, Inc. (US), Omega Diagnostics Group Plc (UK), bioMerieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (Germany), HollisterStier Allergy (US), Eurofins Scientific (Luxembourg), and Stallergenes Greer (UK), among others.

Research Coverage

The report evaluates the allergy diagnostic market and estimates its size and future growth potential across various segments, including product & service, test type, allergen, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report provides valuable data on estimated revenue figures for the overall allergy diagnostic market and its subsegments, benefiting both market leaders and new entrants. It helps stakeholders understand the competitive landscape and gain insights for effectively positioning their businesses and developing appropriate go-to-market strategies. Additionally, the report offers stakeholders an understanding of market trends, including key drivers, challenges, obstacles, and opportunities within the market.

This report provides insights into the following points:

• Analysis of key drivers (High incidence and heavy economic burden of allergic diseases, Increasing awareness about allergies, Rising environmental pollution levels, Coverage of allergy diagnosis under health insurance schemes), restraints (Premium cost of allergy diagnostic instruments, Lack of adequate knowledge and poor implementation of allergy testing methods, Limited access to healthcare services), opportunities (Limited access to healthcare services, Integration of artificial intelligence in allergy diagnosis), and challenges (Shortage of allergists and lack of training programs, Diagnostic challenges in allergic patients)
• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global allergy diagnostic market
• Market Development: Thorough knowledge and analysis of the profitable rising markets by product & service, test type, allergen, end user, and region
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global allergy diagnostic market
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global allergy diagnostic market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ALLERGY DIAGNOSTIC MARKET OVERVIEW
• 3.2 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY END USER AND COUNTRY
• 3.3 ALLERGY DIAGNOSTIC MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 ALLERGY DIAGNOSTIC MARKET: REGIONAL MIX
• 3.5 ALLERGY DIAGNOSTIC MARKET: DEVELOPED VS. EMERGING ECONOMIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 High incidence and heavy economic burden of allergic diseases
    • 4.2.1.2 Increasing awareness about allergies
    • 4.2.1.3 Rising environmental pollution levels
    • 4.2.1.4 Coverage of allergy diagnosis under health insurance schemes
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Premium cost of allergy diagnostic instruments
    • 4.2.2.2 Lack of adequate knowledge and poor implementation of allergy testing methods
    • 4.2.2.3 Limited access to healthcare services
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Use of mHealth in allergy diagnosis
    • 4.2.3.2 Integration of artificial intelligence in allergy diagnosis
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Shortage of allergists and lack of training programs
    • 4.2.4.2 Diagnostic challenges in allergic patients
• 4.3 UNMET NEEDS & WHITE SPACES
  • 4.3.1 UNMET NEEDS IN ALLERGY DIAGNOSTIC MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL IVD INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL IMMUNOASSAY INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE OF ALLERGY DIAGNOSTIC PRODUCTS, BY PRODUCT & SERVICE, 2025
  • 5.6.2 AVERAGE SELLING PRICE TREND OF ALLERGY DIAGNOSTIC PRODUCTS, BY REGION, 2024-2026
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA FOR HS CODE 902750, 2020-2024
  • 5.7.2 EXPORT DATA FOR HS CODE 902750, 2020-2024
• 5.8 KEY CONFERENCES & EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 EXPANDING ACCESS TO ALLERGY DIAGNOSTICS IN EMERGING MARKETS
  • 5.11.2 SCALING HIGH-THROUGHPUT ALLERGY TESTING IN CENTRALIZED LABORATORIES
  • 5.11.3 IMPROVING PEDIATRIC ALLERGY DIAGNOSIS THROUGH MULTIPLEX TESTING
• 5.12 IMPACT OF 2025 US TARIFF ON ALLERGY DIAGNOSTIC MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON COUNTRIES/REGIONS
    • 5.12.4.1 North America
    • 5.12.4.2 Europe
    • 5.12.4.3 Asia Pacific
  • 5.12.5 END-USE INDUSTRY IMPACT

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 SPECIFIC IGE IMMUNOASSAYS
  • 6.1.2 SKIN PRICK TESTING (SPT)
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 AUTOMATED IMMUNOASSAY ANALYZERS
• 6.3 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3.1 SHORT-TERM (2025-2027) | FOUNDATION & EARLY COMMERCIALIZATION
  • 6.3.2 MID-TERM (2027-2030) | EXPANSION & STANDARDIZATION
  • 6.3.3 LONG-TERM (2030-2035+) | MASS COMMERCIALIZATION & DISRUPTION
• 6.4 PATENT ANALYSIS
  • 6.4.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 6.5 FUTURE APPLICATIONS
  • 6.5.1 ADVANCED MULTIPLEX AND PERSONALIZED ALLERGY DIAGNOSTICS
  • 6.5.2 DIGITAL & AI-ENABLED ALLERGY MONITORING PLATFORMS
  • 6.5.3 AI-INTEGRATED DIGITAL SURGICAL ECOSYSTEMS FOR IOLS
• 6.6 IMPACT OF AI/GEN AI ON ALLERGY DIAGNOSTIC MARKET
  • 6.6.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.6.2 CASE STUDIES OF AI IMPLEMENTATION
  • 6.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.6.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI

7 REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE

• 9.1 INTRODUCTION
• 9.2 CONSUMABLES
  • 9.2.1 RECURRENT USE OF CONSUMABLES FOR ALLERGY DIAGNOSTICS TO DRIVE MARKET
• 9.3 INSTRUMENTS
  • 9.3.1 IMMUNOASSAY ANALYZERS
    • 9.3.1.1 High preference for testing to boost market demand
  • 9.3.2 LUMINOMETERS
    • 9.3.2.1 Convenience and ease of use to propel market growth
  • 9.3.3 OTHER INSTRUMENTS
• 9.4 SERVICES
  • 9.4.1 RISING NEED TO ENSURE EFFECTIVE UTILIZATION OF ALLERGY DIAGNOSTIC PRODUCTS TO SUPPORT MARKET GROWTH

10 ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE

• 10.1 INTRODUCTION
• 10.2 IN VIVO TESTS
  • 10.2.1 SKIN PRICK TESTS
    • 10.2.1.1 Skin prick tests to be most widely preferred in vivo allergy tests
  • 10.2.2 PATCH TESTS
    • 10.2.2.1 Rapid diagnosis of contact dermatitis to boost market demand
  • 10.2.3 OTHER IN VIVO TESTS
• 10.3 IN VITRO TESTS
  • 10.3.1 ABILITY TO IDENTIFY ALLERGEN-SPECIFIC IGE MOLECULES IN PATIENT SERUM TO DRIVE MARKET

11 ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN

• 11.1 INTRODUCTION
• 11.2 INHALED ALLERGENS
  • 11.2.1 HIGH INCIDENCE OF ASTHMA TO BOOST MARKET GROWTH
• 11.3 FOOD ALLERGENS
  • 11.3.1 HIGH PREVALENCE OF FOOD-RELATED ALLERGIES AMONG YOUNG CHILDREN TO SUPPORT MARKET GROWTH
• 11.4 DRUG ALLERGENS
  • 11.4.1 INCREASING INCIDENCE OF DRUG ALLERGIES AND ADVERSE REACTIONS TO DRIVE MARKET
• 11.5 OTHER ALLERGENS

12 ALLERGY DIAGNOSTIC MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 HOSPITAL-BASED LABORATORIES
  • 12.2.1 HOSPIATAL-BASED LABORATORIES TO BE MORE ACCESSIBLE TO PATIENTS AND OFFER RAPID RESULTS
• 12.3 DIAGNOSTIC LABORATORIES
  • 12.3.1 DIAGNOSTIC LABORATORIES TO PIVOTAL FOR DIAGNOSIS AND MANAGEMENT OF ALLERGIES
• 12.4 ACADEMIC RESEARCH INSTITUTES
  • 12.4.1 RISING NUMBER OF INSTITUTES FOR ALLERGY TESTING TRAINING TO SUPPORT MARKET GROWTH
• 12.5 OTHER END USERS

13 ALLERGY DIAGNOSTIC MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 US to dominate North American allergy diagnostic market
  • 13.2.2 CANADA
    • 13.2.2.1 Rising funding activities in allergy diagnostics to drive market
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Increasing prevalence of allergic conditions and rising presence of allergy diagnostic product manufacturers to aid market growth
  • 13.3.2 UK
    • 13.3.2.1 Increasing prevalence of food anaphylaxis to support market growth
  • 13.3.3 FRANCE
    • 13.3.3.1 Increasing reimbursements for allergy testing to spur market growth
  • 13.3.4 ITALY
    • 13.3.4.1 Presence of allergy diagnostic organizations to support increased demand for products
  • 13.3.5 SPAIN
    • 13.3.5.1 Government initiatives and healthcare infrastructural development to drive market
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Rising allergy prevalence and growing research activities to augment market growth
  • 13.4.2 JAPAN
    • 13.4.2.1 Increasing prevalence of allergies among children to propel demand for allergy diagnostics
  • 13.4.3 INDIA
    • 13.4.3.1 Limited awareness regarding allergy management to limit market growth
  • 13.4.4 SOUTH KOREA
    • 13.4.4.1 Rising allergy burden and high diagnostic uptake to fuel South Korean market growth
  • 13.4.5 AUSTRALIA
    • 13.4.5.1 High prevalence of food allergies and major lifestyle changes to drive market
  • 13.4.6 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 High prevalence of childhood asthma to augment market growth
  • 13.5.2 MEXICO
    • 13.5.2.1 Growing focus on awareness training programs to boost market demand
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
• 13.7 GCC COUNTRIES
  • 13.7.1 RISING HEALTHCARE SPENDING TO SPUR MARKET GROWTH

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 14.3 REVENUE ANALYSIS, 2021-2025
• 14.4 MARKET SHARE ANALYSIS
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Product & service footprint
    • 14.5.5.4 Test type footprint
    • 14.5.5.5 Allergen footprint
• 14.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of startups/SMEs
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 FINANCIAL METRICS
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARISON
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 THERMO FISHER SCIENTIFIC INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches & approvals
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 DANAHER CORPORATION
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 MnM view
      • 15.1.2.3.1 Right to win
      • 15.1.2.3.2 Strategic choices
      • 15.1.2.3.3 Weaknesses & competitive threats
  • 15.1.3 SIEMENS HEALTHINEERS AG
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 MnM view
      • 15.1.3.3.1 Right to win
      • 15.1.3.3.2 Strategic choices
      • 15.1.3.3.3 Weaknesses & competitive threats
  • 15.1.4 CANON, INC. (MINARIS MEDICAL AMERICA, INC.)
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Deals
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Right to win
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses & competitive threats
  • 15.1.5 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG)
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Deals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Right to win
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses & competitive threats
  • 15.1.6 EUROFINS SCIENTIFIC
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Expansions
  • 15.1.7 BIOMERIEUX SA
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
  • 15.1.8 DSM ROYAL (ROMER LABS DIVISION HOLDING GMBH)
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 HOLLISTERSTIER ALLERGY (JUBILANT PHARMA)
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
  • 15.1.10 OMEGA DIAGNOSTICS GROUP PLC
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
  • 15.1.11 STALLERGENES GREER LTD.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Deals
• 15.2 OTHER PLAYERS
  • 15.2.1 HOB BIOTECH GROUP CORP., LTD.
  • 15.2.2 HYCOR BIOMEDICAL
  • 15.2.3 LINCOLN DIAGNOSTICS, INC.
  • 15.2.4 R-BIOPHARM AG
  • 15.2.5 ASTRA BIOTECH GMBH
  • 15.2.6 ERBA GROUP
  • 15.2.7 AESKU.GROUP GMBH
  • 15.2.8 ACON LABORATORIES, INC.
  • 15.2.9 ALCIT INDIA PVT. LTD.
  • 15.2.10 BIOPANDA REAGENTS LTD.
  • 15.2.11 BIOSIDE S.R.L.
  • 15.2.12 CREATIVE DIAGNOSTIC MEDICARE PVT. LTD.
  • 15.2.13 DST DIAGNOSTISCHE SYSTEME & TECHNOLOGIEN GMBH
  • 15.2.14 DR. FOOKE LABORATORIEN GMBH

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key secondary sources
    • 16.1.1.2 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Objectives of primary research
    • 16.1.2.2 Key data from primary sources
    • 16.1.2.3 Key industry insights
    • 16.1.2.4 Breakdown of primaries
• 16.2 MARKET SIZE ESTIMATION
  • 16.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 16.2.2 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS
  • 16.2.3 TOP-DOWN APPROACH
  • 16.2.4 DEMAND-SIDE ANALYSIS
• 16.3 DATA TRIANGULATION
• 16.4 MARKET SHARE ESTIMATION
• 16.5 STUDY ASSUMPTIONS
• 16.6 RISK ANALYSIS
• 16.7 RESEARCH LIMITATIONS

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS. SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS